Aerie Pharmaceuticals
AERI
AERI was delisted on the 18th of November, 2022.
175 hedge funds and large institutions have $2.94B invested in Aerie Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 73 increasing their positions, 55 reducing their positions, and 20 closing their positions.
43% more funds holding in top 10
Funds holding in top 10: 7 → 10 (+3)
33% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 55
26% more capital invested
Capital invested by funds: $2.33B → $2.94B (+$615M)
15% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 20
2% more funds holding
Funds holding: 172 → 175 (+3)
40% less call options, than puts
Call options by funds: $20.6M | Put options by funds: $34.6M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
+$20.4M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$18.4M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$14.6M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$13.9M |
| 5 |
BlackRock
New York
|
+$13.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$17.9M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$15.2M |
| 3 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
-$13.6M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$12.1M |
| 5 |
FCMI
Foresite Capital Management II
Larkspur,
California
|
-$11.6M |
AERI Hedge Fund Activity: Q2 2018 in Review
175 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Aerie Pharmaceuticals (AERI) for Q2 2018, worth a combined $2.94B — up 26% from $2.33B a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new AERI positions and 20 closed out — a net gain of 3 holders — while 73 added to existing stakes and 55 trimmed.
The largest buyer was Frontier Capital Management, opening a new position worth an estimated $20.4M. The largest seller was Morgan Stanley, cutting an estimated $17.9M.
- 175 institutional investors held Aerie Pharmaceuticals (AERI) as of Q2 2018, up from 172 in Q1 2018.
- Funds reported $2.94B of Aerie Pharmaceuticals stock for Q2 2018, up 26% quarter-over-quarter.
- 23 funds opened new Aerie Pharmaceuticals positions in Q2 2018 and 20 closed out, a net change of +3 holders.
- The largest Aerie Pharmaceuticals buyer in Q2 2018 was Frontier Capital Management, an estimated $20.4M added.
- The largest Aerie Pharmaceuticals seller in Q2 2018 was Morgan Stanley, an estimated $17.9M sold.
Based on aggregated 13F filings for Q2 2018.